Fundraising Fox
/Companies
Sign in

PanTera

Mol, BE · 4 known investors

Find your way into PanTera

435 people in our graph can introduce you to the PanTera team.

Sign up to see every warm intro you have to PanTera

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the PanTera team. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

PanTera develops actinium-225, a therapeutic radioisotope used in precision cancer treatment through radiotheranostics, serving oncology patients and pharmaceutical companies globally. The company operates a production facility in Belgium producing high-purity actinium-225 as an active pharmaceutical ingredient for personalized nuclear medicine treatments.

BiotechDeep TechHealthtechMedical Devices

Founders & leadership

SVSven van den berghe
Sven van den bergheCEOSven van den Berghe is CEO of PanTera, which produces actinium-225 for precision cancer treatment through radiotheranostics. He has professional experience in nuclear technology and works in Belgium's nuclear energy sector.
CMChristophe Malice
Christophe MaliceCBOCBO of PanTera, which produces actinium-225, a therapeutic radioisotope for precision cancer treatment. He brings experience across business development, corporate strategy, fundraising, M&A, and supply chain management.
SBSamy Bertrand
Samy BertrandFounder
YSYves Sterckx
Yves SterckxDirector of Finance & AdministrationYves Sterckx has 25 years of finance experience across international corporations, with hands-on involvement across finance functions and prior work in Belgium, France, Switzerland, and the Netherlands.
PV
Philippe VanwolleghemDirector Quality, Regulatory Affairs & HSE
SV
Sven Van den BergheFounder

Investors · 4

Koryslisted by KorysHalle · $5.4M

How we know: Korys's portfolio page · Not right? Tell us

Kurma Partnerslisted by Kurma PartnersParis · $162K – $10.8M

How we know: Kurma Partners's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

PMVlisted by PMVBrussels

How we know: PMV's portfolio page · Not right? Tell us

Related companies · 3

ShinefusionShine Fusion develops nuclear technology solutions aimed at building a more sustainable world. The company is focused on advancing nuclear science and related clean energy applications.
TerraPowerTerraPower develops advanced nuclear reactors and related technologies to generate carbon-free electricity and heat for industrial decarbonization, while also producing radioisotopes for medical cancer treatments. The company addresses climate change and energy security through innovative nuclear technology.
Actinium Pharmaceuticals, Inc.Actinium is developing targeted radiotherapy treatments using Actinium-225 and related isotopes for oncology indications including prostate cancer, non-small cell lung cancer, breast cancer, and acute myeloid leukemia. The company's lead candidates include ATNM-400 for solid tumors and Actimab-A for blood malignancies.

Companies working in the same space as PanTera.

Frequently asked questions

What does PanTera do?
PanTera develops actinium-225, a therapeutic radioisotope used in precision cancer treatment through radiotheranostics, serving oncology patients and pharmaceutical companies globally. The company operates a production facility in Belgium producing high-purity actinium-225 as an active pharmaceutical ingredient for personalized nuclear medicine treatments.
Who are PanTera's investors?
PanTera's investors include EQT Life Sciences, Korys, Kurma Partners, PMV.
Where is PanTera headquartered?
PanTera is headquartered in Mol, BE.